Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Snapshot

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0171

Letter to the Editor

Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura

Clin Mol Hepatol. 2022;28(3):575-579. Published online April 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0047

Original Article

The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease

Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah

Clin Mol Hepatol. 2022;28(3):565-574. Published online May 19, 2022

DOI: https://doi.org/10.3350/cmh.2022.0096

Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients

Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):553-564. Published online May 11, 2022

DOI: https://doi.org/10.3350/cmh.2022.0082

Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study

Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi

Clin Mol Hepatol. 2022;28(3):540-552. Published online May 6, 2022

DOI: https://doi.org/10.3350/cmh.2021.0169

Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4

Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao

Clin Mol Hepatol. 2022;28(3):522-539. Published online May 4, 2022

Cited By 1

DOI: https://doi.org/10.3350/cmh.2022.0039

Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults

Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park

Clin Mol Hepatol. 2022;28(3):510-521. Published online March 17, 2022

Cited By 2

DOI: https://doi.org/10.3350/cmh.2021.0332

Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial

Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim

Clin Mol Hepatol. 2022;28(3):497-509. Published online April 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0019

Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals

Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng

Clin Mol Hepatol. 2022;28(3):483-496. Published online March 2, 2022

Cited By 3

DOI: https://doi.org/10.3350/cmh.2021.0406

Editorial

Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults

Byoung Seok Ye

Clin Mol Hepatol. 2022;28(3):481-482. Published online May 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0097

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease

Seonghwan Hwang, Won Kim

Clin Mol Hepatol. 2022;28(3):478-480. Published online June 16, 2022

DOI: https://doi.org/10.3350/cmh.2022.0143

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

Review

Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases

Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim

Clin Mol Hepatol. 2022;28(3):425-472. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0186

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

Cited By 3

DOI: https://doi.org/10.3350/cmh.2022.0012

Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance

Mina Komuta

Clin Mol Hepatol. 2022;28(3):396-407. Published online January 14, 2022

Cited By 1

DOI: https://doi.org/10.3350/cmh.2021.0287

Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?

Myung Ji Goh, Dong Hyun Sinn

Clin Mol Hepatol. 2022;28(3):380-395. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0366

Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound

Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, Jeong Hee Yoon

Clin Mol Hepatol. 2022;28(3):362-379. Published online December 27, 2021

DOI: https://doi.org/10.3350/cmh.2021.0361

The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection

Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee

Clin Mol Hepatol. 2022;28(3):351-361. Published online November 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0281

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350. Published online October 19, 2021

Cited By 2

DOI: https://doi.org/10.3350/cmh.2021.0308

Guideline

KASL clinical practice guidelines for management of chronic hepatitis B

Clin Mol Hepatol. 2022;28(2):276-331. Published online April 1, 2022

Cited By 1

DOI: https://doi.org/10.3350/cmh.2022.0084

Snapshot

Acute on chronic liver failure in cirrhosis

Marta Tonon, Salvatore Piano

Clin Mol Hepatol. 2022;28(2):273-275. Published online February 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0036

Letter to the Editor

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

Reply: Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Jihyun An, Ju Hyun Shim

Clin Mol Hepatol. 2022;28(2):267-268. Published online January 18, 2022

DOI: https://doi.org/10.3350/cmh.2022.0013

Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Yi-Chun Huang, Chih-Wei Chen, James Chun-Chung Wei

Clin Mol Hepatol. 2022;28(2):265-266. Published online January 4, 2022

Cited By 1

DOI: https://doi.org/10.3350/cmh.2021.0412

Original Article

Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis

Joonho Jeong, Jung Woo Shin, Seok Won Jung, Eun Ji Park, Neung Hwa Park

Clin Mol Hepatol. 2022;28(2):254-264. Published online December 28, 2021

Cited By 1

DOI: https://doi.org/10.3350/cmh.2021.0314

Cause of death and cause-specific mortality for primary liver cancer in South Korea: A nationwide population-based study in hepatitis B virus-endemic area

Bo Hyun Kim, Dahhay Lee, Kyu-Won Jung, Young-Joo Won, Hyunsoon Cho

Clin Mol Hepatol. 2022;28(2):242-253. Published online February 7, 2022

Cited By 1

DOI: https://doi.org/10.3350/cmh.2021.0355

Galectin-3 inhibits cardiac contractility via a tumor necrosis factor alpha-dependent mechanism in cirrhotic rats

Ki Tae Yoon, Hongqun Liu, Jing Zhang, Sojung Han, Samuel S. Lee

Clin Mol Hepatol. 2022;28(2):232-241. Published online January 5, 2022

Cited By 1

DOI: https://doi.org/10.3350/cmh.2021.0141

Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis

Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song

Clin Mol Hepatol. 2022;28(2):219-231. Published online July 20, 2021

Cited By 3

DOI: https://doi.org/10.3350/cmh.2021.0082

Surgery versus radiofrequency ablation in patients with Child- Pugh class-A/single small (≤3 cm) hepatocellular carcinoma

Jungnam Lee, Young-Joo Jin, Seung Kak Shin, Jung Hyun Kwon, Sang Gyune Kim, Young Ju Suh, Yujin Jeong, Jung Hwan Yu, Jin-Woo Lee, Oh Sang Kwon, Soon Woo Nahm, Young Seok Kim

Clin Mol Hepatol. 2022;28(2):207-218. Published online November 24, 2021

Cited By 1

DOI: https://doi.org/10.3350/cmh.2021.0294

Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: A Korean military population-based cross-sectional study

Jaejun Lee, Taeyun Kim, Hyun Yang, Si Hyun Bae

Clin Mol Hepatol. 2022;28(2):196-206. Published online January 13, 2022

DOI: https://doi.org/10.3350/cmh.2021.0371

Viewed By 10571	Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
Viewed By 3701	Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis
Viewed By 2775	KASL clinical practice guidelines for management of chronic hepatitis B
Viewed By 2535	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease
Viewed By 2016	Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis

Cited By 45	Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017
Cited By 33	Application of transient elastography in nonalcoholic fatty liver disease
Cited By 33	Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Cited By 32	Novel biomarkers for the management of chronic hepatitis B
Cited By 32	KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Article category